Microvascular endothelial cell responses in vitro and in vivo: Modulation by zoledronic acid and paclitaxel?

Journal of Vascular Research

Volumn 47, Issue 6, 2010, Pages 481-493

  Michailidou, Maria ^a   Brown, Hannah K ^a   Lefley, Diane V ^a   Evans, Alyson ^a   Cross, Simon S ^a   Coleman, Robert E ^a   Brown, Nicola J ^a   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Anti angiogenic therapy; Anti vascular therapy; Dorsal microcirculation chamber; Endothelial cells; Paclitaxel; Zoledronic acid

Indexed keywords

PACLITAXEL; PROTEIN; PROTEIN RAP 1A; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; RAP1 PROTEIN; RAP1A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROTUBULE; MICROVASCULATURE; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PRENYLATION; VASCULAR ENDOTHELIUM; ANGIOGENESIS; ANIMAL; CELL CULTURE; CELL CYCLE; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MALE; MICE; MICE, NUDE; MICROVESSELS; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL; PROTEIN PRENYLATION; RAP1 GTP-BINDING PROTEINS; TIME FACTORS;

EID: 77951587849     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313876     Document Type: Article

References (41)

1. Ng SSW, Figg WD, Sparreboom A: Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res 2004; 64: 821-824.
2. Albertsson P, Lennernas B, Norrby K: Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. APMIS 2003; 111 : 995-1003.
3. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D: An-tiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65:2433-2440.
4. Lennernaes B, Albertsson P, Lennernaaes H, Norrby K: Chemotherapy and antiangiogen-esis: drug-specific, dose-related effects. Acta Oncol 2003; 42:294-303. (Pubitemid 36851146)
5. Green JR: Antitumour effects of bisphos-phonates (review). Cancer 2003; 97(suppl): 840-847.
6. Coleman RE: Bisphosphonates in breast cancer. Ann Oncol 2005; 16:687-695.
7. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T: Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10 : 4559-4567.
8. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P: Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Ca ncer Inst 2007; 99: 322-330.
9. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphos-phonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.
10. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P: Bisphos-phonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62 : 6538-65 44.
11. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchi-ni M, Bonsignori M, Tonini G: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893-2897.
12. Zimering MB: Effect of intravenous bisphos-phonates on release of basic fibroblast growth factor in serum of patients with cancer-associated hypercalcemia. Life Sci 2002; 70: 1947-1960.
13. Jagdev SP, Coleman RE, Shipman CM, Ros-tami-H A, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with pacli-taxel. Br J Cancer 2001; 84:1126-1134.
14. Neville-Webbe HL, Evans CA, Coleman RE, Holen I: Mechanisms of the synergistic interaction between the bisphosphonate zole-dronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 2006; 27:92-103.
15. Nogales E, Wolf S, Khan I, Ludueña R, Downing K: Structure of tubulin at 6.5 A and location of the Taxol-binding site. Nature 1995; 75: 424-427.
16. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G: The microtubule-affecting drug paclitax-el has antiangiogenic activity. Clin Cancer Res 1996; 2:1843-1849.
17. Pasquier E, Carre M, Pourroy B, Camoin L, Rebaï O, Briand C, Braguer D: Antiangio-genic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004; 3: 1301-1310.
18. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C: Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278: 43603-43614.
19. Bingle L, Lewis CE, Corke KP, Reed MWR, Brown NJ: Macrophages promote angiogen-esis in human breast tumour spheroids in vivo. Br J Cancer 2006; 94: 101-107.
20. Grant DS, Williams TL, Zahaczewsky M, Dicker AP: Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere). Int J Cancer 2003; 104: 121-129.
21. McTaggart S: Isoprenylated proteins. Cell Mol Life Sci 2006; 63:255-267.
22. Coxon FP, Thompson K, Rogers MJ: Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006; 6: 307-312.
23. Kubista B, Trieb K, Sevelda F, Toma C, Ar-rich F, Heffeter P, Elbling L, Sutterlüty H, Scotlandi K, Kotz R, Micksche M, Berger W: Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006; 24:1145-1152.
24. Davis HW, VandenBerg E, Reid MD, Roy-Chaudhury P, Edwards JD: Paclitaxel impairs endothelial cell adhesion but not cyto-kine-induced cellular adhesion molecule expression. Ann Vasc Surg 2005; 19: 398-406.
25. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I: Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxo-rubicin in breast and prostate cancer cells. Int J Cancer 2005; 113:364-371.
26. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Bri-assoulis E, Efstathiou E, Polyzos A, Fountzi-las G, Christodoulou C, Kouroussis C, Icono-mou T, Gogas H: Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16:950-957. (Pubitemid 40903922)
27. Hassett MJ, O'Malley AJ, Pakes JR, New-house JP, Earle CC: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98: 1108-1117.
28. Hasmim M, Bieler G, Rüegg C: Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signalling pathways. J Thromb Haemost 2006; 5:166-173.
29. Ory B, Blanchard F, Battaglia S, Gouin F, Ré-dini F, Heymann D: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonucle-ase-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007; 71: 333-343.
30. Kuroda J, Kimura S, Segawa H, Sato K, Mat-sumoto S, Nogawa M, Yuasa T, Kobayashi Y, Yoshikawa T, Ottmann OG, Maekawa T: p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zole-dronic acid. Cancer Sci 2004; 95: 186-192.
31. Thompson K, Rogers M, Coxon F, Crockett J: Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006; 69: 1624-1632.
32. Goffinet M, Thoulouzan M, Pradines A, La-joie-Ma zenc I, Weinbaum C , Faye J, Séronie-Vivien S: Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006; 6:60.
33. Wakchoure S, Merrell MA, Aldrich W, Mil-lender-Swain T, Harris KW, Triozzi P, Se-lander KS: Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006; 12: 2862-2868.
34. Walker K, Olson MF: Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 2005; 15: 62-68.
35. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S , Budillon A, Tonini G: Mechanisms of disease: preclinical reports of antineoplas-tic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006; 3:325-338.
36. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL: Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Tax-otere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002; 1:1191-1200.
37. Kubota T, Matsuzaki SW, Hoshiya Y, Wata-nabe M, Kitajima M, Asanuma F, Yamada Y, Koh JI: Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 1997; 64:115-121.
38. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L: Relationship of mi-totic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996; 88: 1308-1313.
39. Zhang AL, Russell PJ: Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice. Ca ncer Lett 2006; 233: 18 5-191.
40. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T: Actions of bisphos-phonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88: 2979-2988.
41. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP: Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103:2289-2295.